Table 1.
Patient characteristics
| Patient characteristics | Total N=104 n (%) |
MRD N=32* n (%) |
UCB N=72 n (%) |
P-value |
|---|---|---|---|---|
|
| ||||
| Age | .67 | |||
| Median (IQR) | 51 (31–59) | 49 (35–56) | 52 (29–60) | |
|
| ||||
| Gender | .79 | |||
| Male | 54 (52) | 16 (50) | 38 (53) | |
|
| ||||
| Cytogenetic risk | ||||
| Unfavorable | 33 (32) | 12 (38) | 21 (29) | .40 |
|
| ||||
| Conditioning regimen | .01 | |||
| Myeloablative | 42 (40) | 19 (59) | 23 (32) | |
| Reduced intensity | 62 (60) | 13 (41) | 49 (68) | |
|
| ||||
| Days from SCT to relapse, | .98 | |||
| Median (IQR) | 152 (77–322) | 104 (87–339) | 168 (74–319) | |
|
| ||||
| Relapse site | .86 | |||
| Systemic | 88 (85) | 28 (87) | 60 (84) | |
| Extramedullar | 16 (15) | 4 (13) | 12 (17) | |
|
| ||||
| BM blast % | .82 | |||
| Median (IQR) | 12 (4–50) | 9 (3–63) | 15 (5–44) | |
|
| ||||
| PB blast % | .17 | |||
| Median (IQR) | 3 (0–15) | 5 (0–15) | 1 (0–20) | |
|
| ||||
| BM donor chimerism | .84 | |||
| Median (IQR) | 69 (32–94) | 78 (47–91) | 63 (32–95) | |
|
| ||||
| Infection at relapse | .03 | |||
| Yes | 20 (19) | 2 (6) | 18 (25) | |
| No | 71 (68) | 25 (78) | 46 (64) | |
| Unknown | 13 (13) | 5 (16) | 8 (11) | |
|
| ||||
| GVHD at relapse | .73 | |||
| Yes | 27 (26) | 7 (21) | 20 (28) | |
| No | 68 (65) | 20 (63) | 48 (67) | |
| Unknown | 9 (9) | 5 (16) | 4 (6) | |
|
| ||||
| Complications at relapse† | .04 | |||
| Yes | 28 (27) | 4 (13) | 24 (33) | |
| No | 62 (60) | 22 (69) | 40 (56) | |
| Unknown | 14 (13) | 6 (19) | 8 (11) | |
|
| ||||
| IST‡ at relapse | .91 | |||
| Yes | 62 (60) | 17 (53) | 45 (63) | |
| No | 28 (27) | 8 (25) | 20 (28) | |
| Unknown | 14 (13) | 7 (22) | 7 (9) | |
*
Graft source, peripheral blood N=28 (88%)
†
Heart failure, arrhythmias, liver, lung, and kidney injury
‡
IST, immunosuppressive therapy